Cancer Prevention Drugs Require Protocol Assessment Before Phase III – FDA
Executive Summary
All oncologic risk reduction drugs should have a special protocol assessment (SPA) before entering Phase III trials, FDA advises staff in a recently issued "Manual of Policies and Procedures" guidance